>65 years with GFR 60‒89 mL/min/1.73 m ^{2}
| P value‡ | General population | P value‡ | |||

Intravenous meloxicam (n=88) | Placebo (n=31) | Intravenous meloxicam (n=449)† | Placebo (n=152) | |||

0‒24 hours | 20.3±21.21 | 35.5±39.24 | 0.0047 | 17.5±23.17 | 20.8±24.40 | 0.0682 |

24‒48 hours¶¶ | 10.4±13.19 | 17.9±29.04 | 0.0334 | 8.3±20.13 | 9.9±19.82 | 0.3259 |

48‒72 hours*** | 5.6±9.91 | 13.0±35.24 | 0.0910 | 3.8±17.54 | 5.0±18.59 | 0.6694 |

0‒48 hours | 30.2±29.29 | 53.5±59.71 | 0.0015 | 25.6±39.16 | 30.3±39.27 | 0.1212 |

0‒72 hours | 32.8±32.45 | 59.4±77.05 | 0.0037 | 27.6±47.60 | 33.0±48.88 | 0.1577 |

During treatment | 35.2±38.96 | 59.4±77.12 | 0.0208 | 28.8±61.05 | 34.8±65.59 | 0.2327 |

*Intravenous morphine equivalent dose (mg).

†Excluded one subject who had erroneous data that cannot be confirmed.

‡P value from analysis of covariance analysis for treatment group difference.

§n=519 for intravenous meloxicam and n=178 for placebo.

¶n=274 for intravenous meloxicam and n=93 for placebo.

**n=275 and 244 for intravenous meloxicam, and n=93 and 85 for placebo, in orthopedic surgery and other surgery, respectively.

††n=126 and 148 for intravenous meloxicam, and n=41 and 52 for placebo, in orthopedic surgery and other surgery, respectively.

‡‡n=406 and 113 for intravenous meloxicam, and n=135 and 43 for placebo, in subjects <65 years and ≥65 years, respectively.

§§n=219 and 55 for intravenous meloxicam, and n=77 and 16 for placebo, in subjects <65 years and ≥65 years, respectively.

¶¶n=83 and 436 for intravenous meloxicam, and n=31 and 147 for placebo, in subjects >65 years with elevated GFR and the general population, respectively.

***n=42 and 232 for intravenous meloxicam, and n=14 and 79 for placebo, in subjects >65 years with elevated GFR and the general population, respectively.

GFR, glomerular filtration rate; SD, standard deviation.